280 related articles for article (PubMed ID: 24556146)
1. Monovalent mannose-based DC-SIGN antagonists: targeting the hydrophobic groove of the receptor.
Tomašić T; Hajšek D; Švajger U; Luzar J; Obermajer N; Petit-Haertlein I; Fieschi F; Anderluh M
Eur J Med Chem; 2014 Mar; 75():308-26. PubMed ID: 24556146
[TBL] [Abstract][Full Text] [Related]
2. Short Communication: Inhibition of DC-SIGN-Mediated HIV-1 Infection by Complementary Actions of Dendritic Cell Receptor Antagonists and Env-Targeting Virus Inactivators.
Pustylnikov S; Dave RS; Khan ZK; Porkolab V; Rashad AA; Hutchinson M; Fieschi F; Chaiken I; Jain P
AIDS Res Hum Retroviruses; 2016 Jan; 32(1):93-100. PubMed ID: 26383762
[TBL] [Abstract][Full Text] [Related]
3. Selective targeting of dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN) with mannose-based glycomimetics: synthesis and interaction studies of bis(benzylamide) derivatives of a pseudomannobioside.
Varga N; Sutkeviciute I; Guzzi C; McGeagh J; Petit-Haertlein I; Gugliotta S; Weiser J; Angulo J; Fieschi F; Bernardi A
Chemistry; 2013 Apr; 19(15):4786-97. PubMed ID: 23417900
[TBL] [Abstract][Full Text] [Related]
4. Mannose hyperbranched dendritic polymers interact with clustered organization of DC-SIGN and inhibit gp120 binding.
Tabarani G; Reina JJ; Ebel C; Vivès C; Lortat-Jacob H; Rojo J; Fieschi F
FEBS Lett; 2006 May; 580(10):2402-8. PubMed ID: 16616922
[TBL] [Abstract][Full Text] [Related]
5. High-affinity glycopolymer binding to human DC-SIGN and disruption of DC-SIGN interactions with HIV envelope glycoprotein.
Becer CR; Gibson MI; Geng J; Ilyas R; Wallis R; Mitchell DA; Haddleton DM
J Am Chem Soc; 2010 Nov; 132(43):15130-2. PubMed ID: 20932025
[TBL] [Abstract][Full Text] [Related]
6. DC-SIGN antagonists, a potential new class of anti-infectives.
Anderluh M; Jug G; Svajger U; Obermajer N
Curr Med Chem; 2012; 19(7):992-1007. PubMed ID: 22257062
[TBL] [Abstract][Full Text] [Related]
7. Unique DC-SIGN clustering activity of a small glycomimetic: A lesson for ligand design.
Sutkeviciute I; Thépaut M; Sattin S; Berzi A; McGeagh J; Grudinin S; Weiser J; Le Roy A; Reina JJ; Rojo J; Clerici M; Bernardi A; Ebel C; Fieschi F
ACS Chem Biol; 2014 Jun; 9(6):1377-85. PubMed ID: 24749535
[TBL] [Abstract][Full Text] [Related]
8. AM3 modulates dendritic cell pathogen recognition capabilities by targeting DC-SIGN.
Serrano-Gómez D; Martínez-Nuñez RT; Sierra-Filardi E; Izquierdo N; Colmenares M; Pla J; Rivas L; Martinez-Picado J; Jimenez-Barbero J; Alonso-Lebrero JL; González S; Corbí AL
Antimicrob Agents Chemother; 2007 Jul; 51(7):2313-23. PubMed ID: 17452477
[TBL] [Abstract][Full Text] [Related]
9. STD NMR and molecular modelling insights into interaction of novel mannose-based ligands with DC-SIGN.
Kotar A; Tomašič T; Lenarčič Živković M; Jug G; Plavec J; Anderluh M
Org Biomol Chem; 2016 Jan; 14(3):862-75. PubMed ID: 26580315
[TBL] [Abstract][Full Text] [Related]
10. Lentivirus-mediated RNA interference of DC-SIGN expression inhibits human immunodeficiency virus transmission from dendritic cells to T cells.
Arrighi JF; Pion M; Wiznerowicz M; Geijtenbeek TB; Garcia E; Abraham S; Leuba F; Dutoit V; Ducrey-Rundquist O; van Kooyk Y; Trono D; Piguet V
J Virol; 2004 Oct; 78(20):10848-55. PubMed ID: 15452205
[TBL] [Abstract][Full Text] [Related]
11. DCIR interacts with ligands from both endogenous and pathogenic origin.
Bloem K; Vuist IM; van den Berk M; Klaver EJ; van Die I; Knippels LM; Garssen J; García-Vallejo JJ; van Vliet SJ; van Kooyk Y
Immunol Lett; 2014; 158(1-2):33-41. PubMed ID: 24239607
[TBL] [Abstract][Full Text] [Related]
12. Comparative analysis reveals selective recognition of glycans by the dendritic cell receptors DC-SIGN and Langerin.
Holla A; Skerra A
Protein Eng Des Sel; 2011 Sep; 24(9):659-69. PubMed ID: 21540232
[TBL] [Abstract][Full Text] [Related]
13. Human seminal plasma abrogates the capture and transmission of human immunodeficiency virus type 1 to CD4+ T cells mediated by DC-SIGN.
Sabatté J; Ceballos A; Raiden S; Vermeulen M; Nahmod K; Maggini J; Salamone G; Salomón H; Amigorena S; Geffner J
J Virol; 2007 Dec; 81(24):13723-34. PubMed ID: 17913809
[TBL] [Abstract][Full Text] [Related]
14. Glycodendrimers prevent HIV transmission via DC-SIGN on dendritic cells.
Garcia-Vallejo JJ; Koning N; Ambrosini M; Kalay H; Vuist I; Sarrami-Forooshani R; Geijtenbeek TB; van Kooyk Y
Int Immunol; 2013 Apr; 25(4):221-33. PubMed ID: 23291968
[TBL] [Abstract][Full Text] [Related]
15. Identification of the DC-SIGN-interactive domains on the envelope glycoprotein of HIV-1 CRF07_BC.
Liao CF; Wang SF; Lin YT; Ho DD; Chen YM
AIDS Res Hum Retroviruses; 2011 Aug; 27(8):831-9. PubMed ID: 21142800
[TBL] [Abstract][Full Text] [Related]
16. Gold manno-glyconanoparticles: multivalent systems to block HIV-1 gp120 binding to the lectin DC-SIGN.
Martínez-Avila O; Hijazi K; Marradi M; Clavel C; Campion C; Kelly C; Penadés S
Chemistry; 2009 Sep; 15(38):9874-88. PubMed ID: 19681073
[TBL] [Abstract][Full Text] [Related]
17. Role of the carbohydrate-binding sites of griffithsin in the prevention of DC-SIGN-mediated capture and transmission of HIV-1.
Hoorelbeke B; Xue J; LiWang PJ; Balzarini J
PLoS One; 2013; 8(5):e64132. PubMed ID: 23741304
[TBL] [Abstract][Full Text] [Related]
18. Cellular uptake of gold nanoparticles bearing HIV gp120 oligomannosides.
Arnáiz B; Martínez-Ávila O; Falcon-Perez JM; Penadés S
Bioconjug Chem; 2012 Apr; 23(4):814-25. PubMed ID: 22433013
[TBL] [Abstract][Full Text] [Related]
19. Human immunodeficiency virus envelope (gp120) binding to DC-SIGN and primary dendritic cells is carbohydrate dependent but does not involve 2G12 or cyanovirin binding sites: implications for structural analyses of gp120-DC-SIGN binding.
Hong PW; Flummerfelt KB; de Parseval A; Gurney K; Elder JH; Lee B
J Virol; 2002 Dec; 76(24):12855-65. PubMed ID: 12438611
[TBL] [Abstract][Full Text] [Related]
20. Non-carbohydrate inhibitors of the lectin DC-SIGN.
Borrok MJ; Kiessling LL
J Am Chem Soc; 2007 Oct; 129(42):12780-5. PubMed ID: 17902657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
